Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Annalisa La Cesa

Showing results (1-10 of 19) with videos related to

Pageof 2
Sort By:
Medical Hypotheses|June 5, 2003
Statins may potentiate bisphosphonates anticancer properties: a new pharmacological approach?Bruno Vincenzi, Daniele Santini, Giuseppe Avvisati, et al.
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|July 13, 2004
Bisphosphonate effects in cancer and inflammatory diseases: in vitro and in vivo modulation of cytokine activitiesDaniele Santini, Maria E Fratto, Bruno Vincenzi, et al.
BMC Cancer|March 1, 2006
Phase I study of intermittent and chronomodulated oral therapy with capecitabine in patients with advanced and/or metastatic cancerDaniele Santini, Bruno Vincenzi, Gaia Schiavon, et al.
Critical Reviews in Oncology/Hematology|September 15, 2004
Predictive factors for response to chemotherapy in colorectal cancer patientsBruno Vincenzi, Annalisa La Cesa, Daniele Santini, et al.
The Breast Journal|April 13, 2020
Repeated courses of radiation treatment in an HER2-positive breast cancer patient with diffuse brain metastases: A case reportSonia Silipigni, Edy Ippolito, Paolo Matteucci, et al.
Anti-Cancer Drugs|September 10, 2003
Raltitrexed-induced hepatotoxicity: multivariate analysis of predictive factorsCristian Massacesi, Daniele Santini, Marco B L Rocchi, et al.
Oncology|October 19, 2006
Capecitabine and mitomycin C is an effective combination for anthracycline- and taxane-resistant metastatic breast cancerCristian Massacesi, Annalisa La Cesa, Fabiana Marcucci, et al.
Oncology|August 10, 2005
Continuous infusion of oxaliplatin plus chronomodulated capecitabine in 5-fluorouracil- and irinotecan-resistant advanced colorectal cancer patientsDaniele Santini, Bruno Vincenzi, Annalisa La Cesa, et al.
Oncology|November 13, 2004
Thymidylate synthase expression in normal colonic mucosa: a predictive marker of toxicity in colorectal cancer patients receiving 5-fluorouracil-based adjuvant chemotherapyDaniele Santini, Bruno Vincenzi, Giuseppe Perrone, et al.
Journal of Interferon & Cytokine Research : the Official Journal of the International Society for Interferon and Cytokine Research|March 16, 2005
Zoledronic acid-related angiogenesis modifications and survival in advanced breast cancer patientsBruno Vincenzi, Daniele Santini, Giordano Dicuonzo, et al.
Pageof 2

Showing results (1-10 of 19) with videos related to

Sort By:
Pageof 2
Medical Hypotheses|June 5, 2003
Statins may potentiate bisphosphonates anticancer properties: a new pharmacological approach?Bruno Vincenzi, Daniele Santini, Giuseppe Avvisati, et al.
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|July 13, 2004
Bisphosphonate effects in cancer and inflammatory diseases: in vitro and in vivo modulation of cytokine activitiesDaniele Santini, Maria E Fratto, Bruno Vincenzi, et al.
BMC Cancer|March 1, 2006
Phase I study of intermittent and chronomodulated oral therapy with capecitabine in patients with advanced and/or metastatic cancerDaniele Santini, Bruno Vincenzi, Gaia Schiavon, et al.
Critical Reviews in Oncology/Hematology|September 15, 2004
Predictive factors for response to chemotherapy in colorectal cancer patientsBruno Vincenzi, Annalisa La Cesa, Daniele Santini, et al.
The Breast Journal|April 13, 2020
Repeated courses of radiation treatment in an HER2-positive breast cancer patient with diffuse brain metastases: A case reportSonia Silipigni, Edy Ippolito, Paolo Matteucci, et al.
Anti-Cancer Drugs|September 10, 2003
Raltitrexed-induced hepatotoxicity: multivariate analysis of predictive factorsCristian Massacesi, Daniele Santini, Marco B L Rocchi, et al.
Oncology|October 19, 2006
Capecitabine and mitomycin C is an effective combination for anthracycline- and taxane-resistant metastatic breast cancerCristian Massacesi, Annalisa La Cesa, Fabiana Marcucci, et al.
Oncology|August 10, 2005
Continuous infusion of oxaliplatin plus chronomodulated capecitabine in 5-fluorouracil- and irinotecan-resistant advanced colorectal cancer patientsDaniele Santini, Bruno Vincenzi, Annalisa La Cesa, et al.
Oncology|November 13, 2004
Thymidylate synthase expression in normal colonic mucosa: a predictive marker of toxicity in colorectal cancer patients receiving 5-fluorouracil-based adjuvant chemotherapyDaniele Santini, Bruno Vincenzi, Giuseppe Perrone, et al.
Journal of Interferon & Cytokine Research : the Official Journal of the International Society for Interferon and Cytokine Research|March 16, 2005
Zoledronic acid-related angiogenesis modifications and survival in advanced breast cancer patientsBruno Vincenzi, Daniele Santini, Giordano Dicuonzo, et al.
Pageof 2